This Article Full Text Full Text (PDF) All Versions of this Article: 110/8/999    most recent 01.CIR.0000139859.68513.FCv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Damås, J. K. Articles by Andreassen, A. K. Search for Related Content PubMed PubMed Citation Articles by Damås, J. K. Articles by Andreassen, A. K. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Pulmonary Hypertension Hazardous Substances DB WARFARIN Related Collections Pulmonary circulation and disease Other anticoagulants Endothelium/vascular type/nitric oxide Other Treatment

(Circulation. 2004;110:999-1005.)
© 2004 American Heart Association, Inc.

Original Articles

Soluble CD40 Ligand in Pulmonary Arterial Hypertension

Possible Pathogenic Role of the Interaction Between Platelets and Endothelial Cells

Jan K. Damås, MD, PhD; Kari Otterdal, MSc; Arne Yndestad, MSc; Halfdan Aass, MD, PhD; Nils O. Solum, PhD; Stig S. Frøland, MD, PhD; Svein Simonsen, MD, PhD; Pål Aukrust, MD, PhD; Arne K. Andreassen, MD, PhD

From the Research Institute for Internal Medicine (J.K.D., K.O., A.Y., N.O.S., S.S.F., P.A.), Department of Cardiology (J.K.D., H.A., S.S., A.K.A.), and Section of Clinical Immunology and Infectious Diseases (S.S.F., P.A.), Rikshospitalet, Oslo, Norway.

Correspondence to Pål Aukrust, Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet, 0027 Oslo, Norway. E-mail pal.aukrust{at}rikshospitalet.no

Received February 24, 2004; accepted April 27, 2004.

Background— Inflammatory processes seem to be involved in pulmonary arterial hypertension (PAH). CD40 ligand (L) may promote inflammation and thrombus formation, and we hypothesized that CD40L could be involved in the pathogenesis of PAH.

Methods and Results— Several significant findings were revealed when examining the possible role of CD40L in PAH. (1) Patients with primary (n=13) and secondary (n=11) PAH but not those with chronic thromboembolic pulmonary hypertension (n=8) had increased plasma levels of soluble (s) CD40L compared with control subjects (n=8). (2) PAH patients using warfarin had markedly lower sCD40L levels than those without such therapy. (3) sCD40L levels were higher in arterial (femoral artery) compared with mixed venous blood (pulmonary artery), suggesting enhanced release or reduced clearance in the pulmonary vasculature. (4) Platelets from PAH patients showed enhanced spontaneous and SFLLRN-stimulated release of sCD40L compared with control subjects. (5) In vitro, recombinant sCD40L induced monocyte chemoattractant protein (MCP)-1 and interleukin-8 gene expression in endothelial cells, and plasma levels of these chemokines were raised in all PAH groups, significantly correlated to sCD40L and hemodynamic parameters. (6) Although prostacyclin therapy (3 months) showed clinical benefit, this therapy had no effect on sCD40L and increased MCP-1 levels in PAH patients, and prostacyclin enhanced MCP-1 in CD40L-stimulated endothelial cells.

Conclusions— Our findings suggest a role for CD40L in the pathogenesis of PAH, possibly operating through an interaction between platelets and endothelial cells involving chemokine-related mechanisms.

Key Words: inflammation • platelets • hypertension, pulmonary • endothelium

This article has been cited by other articles:

				B. Bakouboula, O. Morel, A. Faure, F. Zobairi, L. Jesel, A. Trinh, M. Zupan, M. Canuet, L. Grunebaum, A. Brunette, et al. Procoagulant Membrane Microparticles Correlate with the Severity of Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., March 1, 2008; 177(5): 536 - 543. [Abstract] [Full Text] [PDF]

				K. Otterdal, A. K. Andreassen, A. Yndestad, E. Oie, W. J. Sandberg, C. P. Dahl, T. M. Pedersen, T. Ueland, L. Gullestad, F. R. Brosstad, et al. Raised LIGHT Levels in Pulmonary Arterial Hypertension: Potential Role in Thrombus Formation Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 202 - 207. [Abstract] [Full Text] [PDF]

				O. Sanchez, E. Marcos, F. Perros, E. Fadel, L. Tu, M. Humbert, P. Dartevelle, G. Simonneau, S. Adnot, and S. Eddahibi Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1041 - 1047. [Abstract] [Full Text] [PDF]

				C. Prontera, N. Martelli, V. Evangelista, E. D'Urbano, S. Manarini, A. Recchiuti, A. Dragani, C. Passeri, G. Davi, and M. Romano Homocysteine Modulates the CD40/CD40L System J. Am. Coll. Cardiol., June 5, 2007; 49(22): 2182 - 2190. [Abstract] [Full Text] [PDF]

				J. K. Damas, M. Jensenius, T. Ueland, K. Otterdal, A. Yndestad, S. S. Froland, J.-M. Rolain, B. Myrvang, D. Raoult, and P. Aukrust Increased Levels of Soluble CD40L in African Tick Bite Fever: Possible Involvement of TLRs in the Pathogenic Interaction between Rickettsia africae, Endothelial Cells, and Platelets J. Immunol., August 15, 2006; 177(4): 2699 - 2706. [Abstract] [Full Text] [PDF]

				K. Otterdal, C. Smith, E. Oie, T. M. Pedersen, A. Yndestad, E. Stang, K. Endresen, N. O. Solum, P. Aukrust, and J. K. Damas Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes Blood, August 1, 2006; 108(3): 928 - 935. [Abstract] [Full Text] [PDF]

				S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J. E. Freedman CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2428 - 2434. [Abstract] [Full Text] [PDF]